CENPA promotes glutamine metabolism and tumor progression by up-regulating SLC38A1 in endometrial cancer
Cellular Signalling · 2024
DOI: 10.1016/j.cellsig.2024.111110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2024. Verfasst von Shuang Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei Province, China. Hauptthemen laut MEDLINE: Amino Acid Transport System A, Endometrial Neoplasms, Glutamine, Centromere Protein A. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Glutamine addiction is a significant hallmark of metabolic reprogramming in tumors and is crucial to the progression of cancer. Nevertheless, the regulatory mechanisms of glutamine metabolism in endometrial cancer (EC) remains elusive. In this research, we found that elevated expression of CENPA and solute carrier family 38 member 1 (SLC38A1) were firmly associated with worse clinical stage and unfavorable outcomes in EC patients. In addition, ectopic overexpression or silencing of CENPA could either enhance or diminish glutamine metabolism and tumor progression in EC. Mechanistically, CENPA directly regulated the transcriptional activity of the target gene, SLC38A1, leading to enhanced glutamine uptake and metabolism, thereby promoting EC progression. Notably, a prognostic model utilizing the expression levels of CENPA and SLC38A1 genes independently emerged as a prognostic factor for EC. More importantly, CENPA and SLC38A1 were significantly elevated and positively correlated, as well as indicative of poor prognosis in multiple cancers. In brief, our study confirmed that CENPA is a critical transcription factor involved in glutamine metabolism and tumor progression through modulating SLC38A1. This revelation suggests that targeting CENPA could be an appealing therapeutic approach to address pan-cancer glutamine addiction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei Province, China.
- Department of Gynecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
- Department of Gynecology and Obstetrics, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei Province, China. Electronic address: meimei_xyyy@126.com.
- Department of Gynecology and Obstetrics, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei Province, China. Electronic address: hyq_xyyy@163.com.
Zitieren
APA
Li, S., Zhang, Z., Li, Z., Yang, L., Liu, J., Liu, Y., Liu, Y., Hou, Y., Mei, M., & Huang, Y. (2024). CENPA promotes glutamine metabolism and tumor progression by up-regulating SLC38A1 in endometrial cancer. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2024.111110
Vancouver
Li S, Zhang Z, Li Z, Yang L, Liu J, Liu Y, et al. CENPA promotes glutamine metabolism and tumor progression by up-regulating SLC38A1 in endometrial cancer. Cellular Signalling. 2024. doi:10.1016/j.cellsig.2024.111110
BibTeX
@article{Li2024,
author = {Li, Shuang and Zhang, Zihui and Li, Zhifang and Yang, Lian and Liu, Jianfeng and Liu, Yujie and Liu, Yancai and Hou, Yanmei and Mei, Mei and Huang, Yuqin},
title = {CENPA promotes glutamine metabolism and tumor progression by up-regulating SLC38A1 in endometrial cancer},
journal = {Cellular Signalling},
year = {2024},
doi = {10.1016/j.cellsig.2024.111110}
}
EUVIMED